cis-4-methyl-1-(1-hydroxy-1-methylethyl)cyclohexane | 7322-63-6

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 异戊烯醇脂质
• 英文名称: cis-4-methyl-1-(1-hydroxy-1-methylethyl)cyclohexane
• 英文别名: cis-p-menthan-8-ol；cis-p-menthan-8-ol；1r-Methyl-4c-(α-hydroxy-isopropyl)-cyclohexan；cis-1-Methyl-4-(α-hydroxy-isopropyl)-cyclohexan；cis-1-Methyl-4-<α-hydroxy-isopropyl>-cyclohexan；cis-Dihydro-α-terpineol
• CAS: 7322-63-6
• 化学式: C₁₀H₂₀O
• 分子量: 156.268
• InChiKey: UODXCYZDMHPIJE-DTORHVGOSA-N

物化性质

• 沸点：
  212.2±8.0 °C(Predicted)
• 密度：
  0.899±0.06 g/cm3(Predicted)
• LogP：
  3.061 (est)

计算性质

• 辛醇/水分配系数(LogP)：
  2.58
• 重原子数：
  11.0
• 可旋转键数：
  1.0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  20.23
• 氢给体数：
  1.0
• 氢受体数：
  1.0

反应信息

• 作为反应物：
  描述：

  cis-4-methyl-1-(1-hydroxy-1-methylethyl)cyclohexane 在 potassium hydrogensulfate 作用下， 生成 Cyclohexane, 1-methyl-4-(1-methylethenyl)-, cis-
  参考文献：
  名称：

  Application of1H NMR and13C NMR for establishing the spatial structure of stereoisomeric o- and p-menthane, o- and p-menthenes, and isopropylcyclohexane

  摘要：

  DOI：

  10.1007/bf00612941
• 作为产物：
  描述：

  松油醇 在 platinum(IV) oxide 氢气 作用下， 以 乙醚 为溶剂， 生成 cis-4-methyl-1-(1-hydroxy-1-methylethyl)cyclohexane
  参考文献：
  名称：

  Replacement of Hydrogen at a Tertiary Carbon Atom with OH by Alkaline Permanganate¹

  摘要：

  DOI：

  10.1021/ja01501a033

文献信息

• Tetrahydroxydiboron-Mediated Palladium-Catalyzed Transfer Hydrogenation and Deuteriation of Alkenes and Alkynes Using Water as the Stoichiometric H or D Atom Donor
  作者：Steven P. Cummings、Thanh-Ngoc Le、Gilberto E. Fernandez、Lorenzo G. Quiambao、Benjamin J. Stokes

  DOI：10.1021/jacs.6b02132

  日期：2016.5.18

  There are few examples of catalytic transfer hydrogenations of simple alkenes and alkynes that use water as a stoichiometric H or D atom donor. We have found that diboron reagents efficiently mediate the transfer of H or D atoms from water directly onto unsaturated C-C bonds using a palladium catalyst. This reaction is conducted on a broad variety of alkenes and alkynes at ambient temperature, and boric

  使用水作为化学计量的 H 或 D 原子供体的简单烯烃和炔烃的催化转移氢化的例子很少。我们发现二硼试剂使用钯催化剂有效地介导了 H 或 D 原子从水中直接转移到不饱和 CC 键上。该反应在环境温度下对多种烯烃和炔烃进行，硼酸是唯一的副产物。机理实验表明，该反应是通过从水中的氢原子转移生成 Pd 氢化物中间体而实现的。重要的是，还实现了从化学计量的 D2O 中完全掺入氘。
• METHODS OF TREATMENT COMPRISING THE ADMINISTRATION OF HALOARYL SUBSTITUTED AMINOPURINES OR COMPOSITIONS THEREOF
  申请人：Albers Ronald J.

  公开号：US20090312320A1

  公开（公告）日：2009-12-17

  Provided herein are Aminopurine Compounds having the following structure: wherein R 1 , R 2 and and R 3 are as defined herein, compositions comprising an effective amount of an Aminopurine Compound and methods for treating or preventing cancer, a cardiovascular disease, a renal disease, an autoimmune condition, an inflammatory condition, macular degeneration, ischemia-reperfusion injury, pain and related syndromes, disease-related wasting, an asbestos-related condition, pulmonary hypertension or a condition treatable or preventable by inhibition of the JNK pathway comprising administering an effective amount of an Aminopurine Compound to a patient in need thereof.

  本文提供具有以下结构的氨基嘌呤化合物：其中R1、R2和R3如下定义，包含有效量的氨基嘌呤化合物的组合物以及治疗或预防癌症、心血管疾病、肾脏疾病、自身免疫疾病、炎症性疾病、黄斑变性、缺血再灌注损伤、疼痛和相关综合症、疾病相关消耗、石棉相关疾病、肺动脉高压或可通过抑制JNK通路治疗或预防的疾病的方法，包括向需要的患者施用有效量的氨基嘌呤化合物。
• HALOARYL SUBSTITUTED AMINOPURINES, COMPOSITIONS THEREOF,AND METHODS OF TREATMENT THEREWITH
  申请人：Signal Pharmaceuticals, LLC

  公开号：US20140206697A1

  公开（公告）日：2014-07-24

  Provided herein are Aminopurine Compounds having the following structure: wherein R 1 , R 2 and R 3 are as defined herein, compositions comprising an effective amount of an Aminopurine Compound and methods for treating or preventing cancer, a cardiovascular disease, a renal disease, an autoimmune condition, an inflammatory condition, macular degeneration, ischemia-reperfusion injury, pain and related syndromes, disease-related wasting, an asbestos-related condition, pulmonary hypertension or a condition treatable or preventable by inhibition of the JNK pathway comprising administering an effective amount of an Aminopurine Compound to a patient in need thereof.

  本文提供具有以下结构的氨基嘌呤化合物：其中R1、R2和R3的定义如本文所述，包含有效量的氨基嘌呤化合物的组合物以及治疗或预防癌症、心血管疾病、肾脏疾病、自身免疫疾病、炎症性疾病、黄斑变性、缺血再灌注损伤、疼痛及相关综合症、与疾病相关的消耗、石棉相关疾病、肺动脉高压或通过抑制JNK途径可治疗或预防的疾病的方法，包括向需要治疗的患者施用有效量的氨基嘌呤化合物。
• Diastereoselective Hydrogenation of Tetrasubstituted Olefins using a Heterogeneous Pt‐Ni Alloy Catalyst
  作者：William A. Swann、Anish Yadav、Nicholas B. Colvin、Nicole K. Freundl、Christina W. Li

  DOI：10.1002/anie.202317710

  日期：2024.5.6

  A Pt−Ni alloy nanocatalyst is developed for the diastereoselective directed hydrogenation of tetrasubstituted olefins in a cyclopentene scaffold. For this substrate class, established homogeneous catalysts generate hydrogenolysis side products, and commercial heterogeneous catalysts are not stereoselective. Uniform alloying of the noble metal and base metal combined with high catalyst dispersion is

  开发了一种 Pt-Ni 合金纳米催化剂，用于环戊烯支架中四取代烯烃的非对映选择性定向氢化。对于此类底物，已建立的均相催化剂会产生氢解副产物，而商业多相催化剂不具有立体选择性。贵金属和贱金属的均匀合金化与高催化剂分散相结合对于一系列空间位阻烯烃的良好反应性和非对映选择性至关重要。
• Directing effects in homogeneous hydrogenation with [Ir(cod)(PCy3)(py)]PF6
  作者：Robert H. Crabtree、Mark W. Davis

  DOI：10.1021/jo00364a007

  日期：1986.7

表征谱图